Health and Healthcare
Regenerative Medicine Company on Track for IPO This Week
Published:
Last Updated:
No IPOs made an entrance in the short holiday week. IPO ETF manager Renaissance Capital reported that 261 IPOs have priced in the United States so far this year, up about 25% from a year ago. Total proceeds raised come to $82 billion, up more than 66% from 2013. The 2013 IPO total came in at $54.9 billion, the highest total in the past 10 years.
There is just one IPO on the schedule for the week of December 1. Histogenics Corp. is a regenerative medicine company that is developing and commercializing products in the musculoskeletal market. The company plans to offer 4.3 million shares in an IPO price range of $13 to $15, raising $60 million at a market cap of about $151 million. Joint bookrunners for the offering are Cowen, Needham and Canaccord Genuity. Co-manager is BTIG. The stock is expected to price on Tuesday and begin trading Wednesday on the Nasdaq under the ticker symbol HSGX.
As of Sunday there is just one IPO scheduled for the week of December 8 as well. We’ll have more on that one, a REIT that focuses on the Nordic countries, and any others that pop up in our next report.
ALSO READ: 5 Health Care Stocks That Need to Play Serious Catch Up
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.